Turning Point Therapeutics Reports Second-Quarter 2022 Financial Results, Provides Operational Updates
08 août 2022 16h17 HE
|
Turning Point Therapeutics, Inc.
Positive feedback from pre-new drug application (NDA) meeting with U.S. Food and Drug Administration (FDA) focused on TRIDENT-1 registrational study of repotrectinibInitiated the Phase 1b/2 SHIELD-2...
Turning Point Therapeutics Provides Regulatory Update for Repotrectinib for the Treatment of ROS1+ Advanced NSCLC
27 juil. 2022 16h05 HE
|
Turning Point Therapeutics, Inc.
SAN DIEGO, July 27, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer...
Turning Point Therapeutics and MD Anderson Announce Strategic Alliance to Advance Precision Cancer Therapies
24 juin 2022 09h00 HE
|
Turning Point Therapeutics, Inc.
HOUSTON and SAN DIEGO, June 24, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted...
Turning Point Therapeutics to Participate in Upcoming Investor Conferences
26 mai 2022 16h30 HE
|
Turning Point Therapeutics, Inc.
SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer...
Turning Point Therapeutics Announces Appointment of Steve Sabus as Chief Commercial Officer
16 mai 2022 08h30 HE
|
Turning Point Therapeutics, Inc.
SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer...
Turning Point Therapeutics Reports First-Quarter 2022 Financial Results, Provides Operational Updates
10 mai 2022 16h05 HE
|
Turning Point Therapeutics, Inc.
Granted Third Breakthrough Therapy Designation (BTD) for Repotrectinib for the treatment of patients with ROS1-positive Metastatic NSCLC who have been Previously Treated with One ROS1 TKI and who have...
Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients With One Prior ROS1 Tyrosine Kinase Inhibitor and no Prior Chemotherapy
10 mai 2022 08h30 HE
|
Turning Point Therapeutics, Inc.
SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer...
Turning Point Therapeutics Announces Pipeline Expansion, Licensing of TPX-4589 (LM-302), A Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate for Gastrointestinal Cancers, From Lanova Medicines
05 mai 2022 09h00 HE
|
Turning Point Therapeutics, Inc.
Strategic Expansion of Turning Point Precision Oncology Portfolio TPX-4589 (LM-302) Currently in Two Ongoing Phase 1 Studies Agreement Includes Potential Broader Scope to Collaborate on up to Three...
Turning Point Therapeutics and Zai Lab Announce Topline Analysis in China Subpopulation for Repotrectinib in ROS1-Positive NSCLC Cohorts Within Global Phase 1/2 TRIDENT-1 Study
28 avr. 2022 07h30 HE
|
Turning Point Therapeutics, Inc.
91% confirmed objective response rate (cORR) (10/11) in China subpopulation by Blinded Independent Central Review (BICR) in TKI-naïve cohort (EXP-1) In the TKI-naïve China subpopulation by BICR, the...
Turning Point Therapeutics Announces Positive Topline Data by Blinded Independent Central Review for Repotrectinib Across All ROS1-Positive NSCLC Cohorts of Phase 1/2 TRIDENT-1 Study
12 avr. 2022 16h46 HE
|
Turning Point Therapeutics, Inc.
In a total of 71 TKI-naïve patients, confirmed objective response rate (cORR) of 79% (95% CI: 68, 88)In the TKI-naïve population with approximately 10 months of follow-up, initial estimated durability...